<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04503915</url>
  </required_header>
  <id_info>
    <org_study_id>HRT-E2</org_study_id>
    <nct_id>NCT04503915</nct_id>
  </id_info>
  <brief_title>Estrogen Supplementation Mode in HRT-FET Cycle: a RCT</brief_title>
  <official_title>A Multicenter Randomized Controlled Trial Comparing a Step-wise Increase Versus a Constant Dose of Estrogen Supplementation in Frozen-thawed Embryo Transfer Cycles Using Hormone Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A systematic review and meta-analysis concluded that there is insufficient evidence to&#xD;
      recommend one particular protocol for HRT with regard to pregnancy rates after frozen embryo&#xD;
      transfer, and no comparison of estrogen dose or route of administration was included in the&#xD;
      review[7]. It is worth highlighting that the authors did not find any literature discussing&#xD;
      the effect of estrogen dose and route of administration for HRT on reproductive outcomes. In&#xD;
      2016, a retrospective cohort study concluded that there is no difference in live birth rates&#xD;
      between a constant dose versus an increasing dose of estrogen in oocyte donation cycles with&#xD;
      oral or transdermal supplementation[6]. In order to provide good evidence about pattern of&#xD;
      estrogen supplementation in HRT-FET, a randomized controlled study is urgently needed.&#xD;
&#xD;
      The present randomized controlled study aims to compare between a constant estrogen dose&#xD;
      protocol and a step-wise increasing estrogen dose protocol on the live birth rate of HRT-FET&#xD;
      cycles.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective is to compare between a constant estrogen dose protocol and a step-wise&#xD;
      increasing estrogen dose protocol on live birth rate of HRT-FET cycles.&#xD;
&#xD;
      This is a multicenter randomized controlled trial. Women undergoing HRT-FET will be recruited&#xD;
      and randomized to use a constant estrogen dose protocol and a step-wise increasing estrogen&#xD;
      dose protocol.&#xD;
&#xD;
      Participation in the study is totally voluntary. The subjects can withdraw from the study at&#xD;
      any time and they will still receive standard medical care.&#xD;
&#xD;
      Women being scheduled for HRT-FET will be assessed for eligibility. Eligible women will be&#xD;
      recruited in the study and each woman will only be included in the study once.&#xD;
&#xD;
      Informed written consent will be obtained prior to recruitment. The baseline characteristics&#xD;
      will be collected. Transvaginal ultrasound will be done to measure the endometrial thickness&#xD;
      on the day of progesterone supplementation. Embryo transfer will be performed 3 days or 5&#xD;
      days after progesterone use, depending on replacement of cleaving stage embryos or&#xD;
      blastocysts respectively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>live-birth rate per ET</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Live birth was defined as the delivery of at least one live born baby beyond 28 weeks of gestation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical pregnancy rate</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>- clinical pregnancy: presence of intrauterine gestational sac on pelvic ultrasound at 6 weeks of gestation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">784</enrollment>
  <condition>Hormone Replacement Therapy</condition>
  <condition>Estrogen</condition>
  <condition>Live Birth Rate</condition>
  <arm_group>
    <arm_group_label>Constant group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women will receive oral estradiol valerate (ProgynovaÂ®; Bayer Schering Pharma AG, Berlin, Germany) 3 mg bid for 14 days for endometrial priming from the second or third day of the menstrual cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step -up group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women will receive estradiol valerate 2mg once daily for 4 days from the second to fifth day,followed by 2mg bid for 4 days from the sixth to ninth day and then 3mg bid for 6 days from tenth to fifteenth day of menstrual cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>different estrogen supplementation modes</intervention_name>
    <description>The different estrogen supplementation modes are randomized into two groups.</description>
    <arm_group_label>Constant group</arm_group_label>
    <arm_group_label>Step -up group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women aged &lt;42 years at the time of HRT-FET&#xD;
&#xD;
          -  Replacing 1-2 early cleavage embryos or blastocysts after thawing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Preimplantation genetic testing(PGT)&#xD;
&#xD;
          -  Use of donor oocytes&#xD;
&#xD;
          -  Hydrosalpinx shown on pelvic scanning and not surgically treated such as tubal&#xD;
             ligation or resection&#xD;
&#xD;
          -  Severe uterine adhesion&#xD;
&#xD;
          -  The endometrial thickness cannot reach 8mm in previous fresh cycles or HRT -FET cycles&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi Zhang</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haiyan Lin</last_name>
    <phone>15913154456</phone>
    <email>709235159@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qingxue Zhang</last_name>
    <phone>81332233</phone>
    <phone_ext>13602797433</phone_ext>
    <email>zhangqingxue666@aliyun.com</email>
  </overall_contact_backup>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 27, 2020</study_first_submitted>
  <study_first_submitted_qc>August 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2020</study_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Haiyan Lin</investigator_full_name>
    <investigator_title>Attending physician</investigator_title>
  </responsible_party>
  <keyword>estrogen supplementation</keyword>
  <keyword>HRT</keyword>
  <keyword>Live birth rate</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Until the completion of the study.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

